Shots:
- HUTCHMED has initiated a P-III trial of HMPL-760 + R-GemOx (rituximab, gemcitabine and oxaliplatin) in r/r DLBCL Chinese pts, with first patient dosing achieved on Mar 20, 2026
- Trial will evaluate efficacy, safety, & PK of HMPL-760 vs PBO, both in combination with R-GemOx in r/r DLBCL pts (n=~240) who are who are relapsed or refractory after prior treatment with 1L systemic therapy & ineligible for transplantation
- P-III trial initiation was supported by the P-II study evaluating HMPL-760 + R-GemOx in r/r DLBCL, which showed improvements across ORR, CRR, PFS & OS, with favorable safety
Ref: Globenewswire| Image: HUTCHMED | Press Release
Related News: HUTCHMED Initiates P-III Trial of Surufatinib + Camrelizumab + CT for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
